Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846794 | 0.73 | BRD4 (0.42) | — | |
| SCHEMBL9869833 | 0.67 | CACNA1F (0.42) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL14264660 | 0.66 | CYP19A1 (0.59) | BACE1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5580256 | 0.66 | TDP1 (0.56) | BACE1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL25327137 | 0.64 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL4023245 | 0.63 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4NPSR1 | |
| SCHEMBL11404396 | 0.62 | SLC40A1 (0.36) | SLC6A2SLC6A3SLC6A4ABCC9ABCC8 | |
| Dichlormezanone SCHEMBL29854540 | 0.62 | LMNA (0.72) | BACE1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| Dichlormezanone SCHEMBL2107746 | 0.62 | LMNA (0.72) | BACE1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL8437322 | 0.61 | NPSR1 (0.49) | SLC6A2SLC6A3SLC6A4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | claimed |
| EP-1625214-A1 | NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS | Amsterdam Institute of Viral Genomics B.V. (NL) | 2006-02-15 | — | — | EP | claimed |
| WO-2004104189-A1 | NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS | AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) | 2004-12-02 | — | — | WO | claimed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024233354-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20060182762-A1 | Enterovirus, vaccines, medicaments and diagnostic kits | AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) | 2006-08-17 | — | — | US | disclosed |
| EP-1625214-A1 | NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS | Amsterdam Institute of Viral Genomics B.V. (NL) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004104189-A1 | NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS | AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182762-A1 | Enterovirus, vaccines, medicaments and diagnostic kits | CD99, CD63, FAM83B | BACE1 4141/4885SLC6A2 4412/4885SLC6A3 4397/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | BACE1 4573/4885SLC6A2 929/4885SLC6A3 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.